We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Hand osteoarthritis is a degenerative joint disease in which the smooth cartilage that covers the bone surfaces at the joints either is injured or wears over time. touchIMMUNOLOGY were delighted to speak with Dr Anna Døssing (The Parker Institute, University of Copenhagen Copenhagen, Denmark) about hand osteoarthritis and the challenges in its treatment. The abstract […]
There is a lack of biomarkers to profile phenotypes in giant cell arteritis (GCA) and predict potential complications. Serum protein profiling may identify molecular-based phenotypes and facilitate personalized medicine approaches. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about her study which investigated the serum protein signature of clinically defined GCA […]
Giant cell arteritis (GCA) is a primary systemic vasculitis characterised by systemic inflammation and vascular insufficiency of large and medium blood vessels which may lead to end-organ damage in patients age 50 and older. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about the unmet needs in the pathogenesis of […]
WCO-IOF-ESCEO took place between 4-7 May and brought all of the latest clinical findings and advances in osteoporosis, osteoarthritis and musculoskeletal diseases. We were delighted to talk with Editorial Board member Prof. Nicholas Fuggle (MRC Life Force Epidemiology Centre, University of Southampton, UK) around his personal highlights from this year’s conference and the most promising […]
Novel oral bisphosphonate formulations have been developed to address poor adherence to conventional bisphosphonates associated with the difficulty and inflexibility of dosing in osteoporosis preventative treatment. We were delighted to talk with Editorial Board member Prof. Nicholas Fuggle (MRC Life Force Epidemiology Centre, University of Southampton, UK) to discuss the novel oral bisphosphonates, buffered effervescent […]
A digital tool for self management in osteoporosis has recently been developed to reach older patients in their own homes using the Amazon Alexa app, to improve patient adherence and outcomes. touchIMMUNOLOGY caught up with Dr. David Scott (Deakin University, Melbourne, Australia) to discuss how eHealth will support patients in self-management, how this novel technological […]
The phase 3 LIBERTY-EoE-TREET study (NCT03633617) evaluated the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic oesophagitis. We caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the part C subgroup analysis, which investigated the effect of prior topical corticosteroid use on the efficacy of […]
Dupilumab is a fully human monoclonal antibody that inhibits the interleukin-4 and interleukin-13 pathways, and has been approved for the treatment of eosinophilic oesophagitis in the USA and Europe. touchIMMUNOLOGY caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the burden of eosinophilic oesophagitis, limitations of current therapeutic options, […]
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Get the latest clinical insights from touchIMMUNOLOGY